BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 21855037)

  • 21. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus.
    Ishikura S; Nihei K; Ohtsu A; Boku N; Hironaka S; Mera K; Muto M; Ogino T; Yoshida S
    J Clin Oncol; 2003 Jul; 21(14):2697-702. PubMed ID: 12860946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical results of definitive chemoradiotherapy for patients with synchronous head and neck squamous cell carcinoma and esophageal cancer.
    Shinoto M; Shioyama Y; Sasaki T; Nakamura K; Ohura H; Toh Y; Higaki Y; Yamaguchi T; Ohnishi K; Atsumi K; Hirata H; Honda H
    Am J Clin Oncol; 2011 Aug; 34(4):362-6. PubMed ID: 20686402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma.
    Malaisrie SC; Hofstetter WL; Correa AM; Ajani JA; Komaki RR; Rice DC; Vaporciyan AA; Walsh GL; Roth JA; Wu TT; Swisher SG
    Cancer; 2006 Sep; 107(5):967-74. PubMed ID: 16874819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study.
    Choi N; Park SD; Lynch T; Wright C; Ancukiewicz M; Wain J; Donahue D; Mathisen D
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):111-22. PubMed ID: 15337546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concurrent chemoradiotherapy for esophageal cancer: comparison between intermittent standard-dose cisplatin with 5-fluorouracil and daily low-dose cisplatin with continuous infusion of 5-fluorouracil.
    Sai H; Mitsumori M; Yamauchi C; Araki N; Okumura S; Nagata Y; Nishimura Y; Hiraoka M
    Int J Clin Oncol; 2004 Jun; 9(3):149-53. PubMed ID: 15221597
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial.
    Crosby T; Hurt CN; Falk S; Gollins S; Mukherjee S; Staffurth J; Ray R; Bashir N; Bridgewater JA; Geh JI; Cunningham D; Blazeby J; Roy R; Maughan T; Griffiths G
    Lancet Oncol; 2013 Jun; 14(7):627-37. PubMed ID: 23623280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
    Hitt R; López-Pousa A; Martínez-Trufero J; Escrig V; Carles J; Rizo A; Isla D; Vega ME; Martí JL; Lobo F; Pastor P; Valentí V; Belón J; Sánchez MA; Chaib C; Pallarés C; Antón A; Cervantes A; Paz-Ares L; Cortés-Funes H
    J Clin Oncol; 2005 Dec; 23(34):8636-45. PubMed ID: 16275937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response.
    Barbour AP; Jones M; Gonen M; Gotley DC; Thomas J; Thomson DB; Burmeister B; Smithers BM
    Ann Surg Oncol; 2008 Oct; 15(10):2894-902. PubMed ID: 18663531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of age in the radical treatment of oesophageal cancer with surgery or chemoradiotherapy: a prospective observational cohort study.
    Davies L; Lewis WG; Arnold DT; Escofet X; Blackshaw G; Gwynne S; Evans M; Roberts SA; Appadurai I; Crosby TD
    Clin Oncol (R Coll Radiol); 2010 Sep; 22(7):578-85. PubMed ID: 20591633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Concurrent chemoradiotherapy with nedaplatin and 5-fluorouracil (5-fu) for locally advanced squamous cell carcinoma of the esophagus].
    Kubo N; Morimoto J; Tanaka H; Ohira M; Noda E; Amano R; Inoue T; Yamada N; Yashiro M; Maeda K; Yamashita Y; Muguruma K; Sawada T; Hirakawa K
    Gan To Kagaku Ryoho; 2009 Nov; 36(12):1997-9. PubMed ID: 20037303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concurrent chemoradiotherapy or endoscopic stenting for advanced squamous cell carcinoma of esophagus: a case-control study.
    Wong SK; Chiu PW; Leung SF; Cheung KY; Chan AC; Au-Yeung AC; Griffith JF; Chung SS; Ng EK
    Ann Surg Oncol; 2008 Feb; 15(2):576-82. PubMed ID: 18057993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison between radical esophagectomy and definitive chemoradiotherapy in patients with clinical T1bN0M0 esophageal cancer.
    Motoori M; Yano M; Ishihara R; Yamamoto S; Kawaguchi Y; Tanaka K; Kishi K; Miyashiro I; Fujiwara Y; Shingai T; Noura S; Ohue M; Ohigashi H; Nakamura S; Ishikawa O
    Ann Surg Oncol; 2012 Jul; 19(7):2135-41. PubMed ID: 22302264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903).
    Katakami N; Tada H; Mitsudomi T; Kudoh S; Senba H; Matsui K; Saka H; Kurata T; Nishimura Y; Fukuoka M
    Cancer; 2012 Dec; 118(24):6126-35. PubMed ID: 22674529
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma.
    Lee J; Im YH; Cho EY; Hong YS; Lee HR; Kim HS; Kim MJ; Kim K; Kang WK; Park K; Shim YM
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):77-84. PubMed ID: 17762932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with cisplatin concurrent chemoradiotherapy for nonmetastatic Stage IV head-and-neck squamous cell carcinomas.
    Prestwich RJ; Öksüz DÇ; Dyker K; Coyle C; Şen M
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e237-43. PubMed ID: 21620580
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Scoring system for predicting recurrence after chemoradiotherapy including 5-fluorouracil and platinum for patients with esophageal cancer.
    Kogo M; Suzuki A; Sunaga T; Kaneko K; Imawari M; Kiuchi Y
    Hepatogastroenterology; 2013; 60(128):1979-84. PubMed ID: 24088316
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemoradiation for esophageal cancer: institutional experience with three different regimens.
    Courrech Staal EF; Aleman BM; van Velthuysen ML; Cats A; Boot H; Jansen EP; van Coevorden F; van Sandick JW
    Am J Clin Oncol; 2011 Aug; 34(4):343-9. PubMed ID: 20562589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival after definitive (chemo)radiotherapy in esophageal cancer patients: a population-based study in the north-East Netherlands.
    Smit JK; Muijs CT; Burgerhof JG; Paardekooper G; Timmer PR; Muller K; Woutersen D; Mul VE; Beukema JC; Hospers GA; van Dijk BA; Langendijk JA; Plukker JT
    Ann Surg Oncol; 2013 Jun; 20(6):1985-92. PubMed ID: 23274534
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ten-year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus.
    Bidoli P; Bajetta E; Stani SC; De CD; Santoro A; Valente M; Zucali R; Valagussa P; Ravasi G; Bonadonna G
    Cancer; 2002 Jan; 94(2):352-61. PubMed ID: 11900221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of adenocarcinoma of the esophagus with chemoradiation alone or chemoradiation followed by esophagectomy: results of sequential nonrandomized phase II studies.
    Algan O; Coia LR; Keller SM; Engstrom PF; Weiner LM; Schultheiss TE; Hanks GE
    Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):753-61. PubMed ID: 7790262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.